# EDGAR Filing Document

**Accession Number:** 0001356576
**File Stem:** 0002117599-26-000002
**Filing Date:** 2026-3
**Character Count:** 10536
**Document Hash:** 66f5b875d89fd03ff6bb7333884cbb03
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002117599-26-000002.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0002117599-26-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260301

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Horich William Todd
- **CENTRAL INDEX KEY:** 0002117599

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35518
- **FILM NUMBER:** 26739380

**MAIL ADDRESS:**
- **STREET 1:** C/O SUPERNUS PHARMACEUTICALS, INC.
- **STREET 2:** 9715 KEY WEST AVENUE
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SUPERNUS PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001356576
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 9715 KEY WEST AVENUE
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-838-2500

**MAIL ADDRESS:**
- **STREET 1:** 9715 KEY WEST AVENUE
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUPERNUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20060317

## Ex-24

![](supernus-toddhorichpoa001.jpg)

57300106.1 Power of Attorney Know all by these presents, that the undersigned hereby constitutes and appoints JACK KHATTAR and TIMOTHY DEC, and each of them individually, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Supernus Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and condition as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in- fact, or each such attorney-in- fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact. IN WITNESS THEREOF, the undersigned has caused this Power of Attorney to be executed as of this third day of March, 2026. /s/ William Todd Horich William Todd Horich

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Horich William Todd<br><sub>(Last) (First) (Middle)</sub><br>C/O SUPERNUS PHARMACEUTICALS, INC.,<br>9715 KEY WEST AVENUE<br><sub>(Street)</sub><br>ROCKVILLE, MD 20850<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, Commercial Operations_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 4832 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | <sup>(1)</sup> | 2028-02-14 | Common Stock | 13000 | $39.40 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(2)</sup> | 2029-02-22 | Common Stock | 14000 | $36.75 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(3)</sup> | 2031-02-19 | Common Stock | 17000 | $29.61 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-02-22 | Common Stock | 18000 | $32.20 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(5)</sup> | 2033-02-23 | Common Stock | 20000 | $38.60 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(6)</sup> | 2034-02-22 | Common Stock | 25000 | $27.94 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(7)</sup> | 2035-02-19 | Common Stock | 20000 | $33.52 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(8)</sup> | 2036-02-18 | Common Stock | 13500 | $50.20 | D |  |
| Restricted Stock Unit | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 6250 | <sup>(10)</sup> | D |  |
| Restricted Stock Unit | <sup>(11)</sup> | <sup>(11)</sup> | Common Stock | 2500 | <sup>(10)</sup> | D |  |
| Restricted Stock Unit | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 3375 | <sup>(10)</sup> | D |  |
| Restricted Stock Unit | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 3000 | <sup>(10)</sup> | D |  |
| Performance Share Unit | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 3750 | $0 | D |  |
| Performance Share Unit | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 1125 | $0 | D |  |
| Performance Share Unit | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 2625 | $0 | D |  |

---

### Footnotes:

(1) The option vests in four equal annual installments beginning on February 14, 2019.

(2) The option vests in four equal annual installments beginning on February 22, 2020.

(3) The option vests in four equal annual installments beginning on February 19, 2022.

(4) The option vests in four equal annual installments beginning on February 22, 2023.

(5) The option vests in four equal annual installments beginning on February 23, 2024.

(6) The option vests in four equal annual installments beginning on February 22, 2025.

(7) The option vests in four equal annual installments beginning on February 19, 2026.

(8) The option vests in four equal annual installments beginning on February 18, 2027.

(9) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

(10) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

(11) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

(12) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

(13) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

(14) On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a definedperformance period, which objectives were established on June 24, 2024.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Timothy C. Dec, as attorney-in-fact  
**Date:** 2026-03-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**